Myocardial cell sheet therapy and cardiac function

Jun Fujita, Yuji Itabashi, Tomohisa Seki, Shugo Tohyama, Yuichi Tamura, Motoaki Sano, Keiichi Fukuda

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Heart failure (HF) is the leading cause of death in developed countries. Regenerative medicine has the potential to drastically improve treatment for advanced HF. Stem cell-based medicine has received attention as a promising candidate therapy over the past decade; however, it has not yet realized this potential in terms of reliability. The cell sheet is an innovative technology for constructing aligned graft cells, and several cell sources have been investigated for making a feasible cell sheet. The most representative thus far is skeletal myoblast, although such cells raise the issue of arrhythmogenicity. Regenerative cardiomyocytes (CMs) derived from pluripotent stem cells (PSCs), such as embryonic stem cells or induced PSCs, are the most promising, because a myocardial cell sheet (MCS) constructed with regenerative CMs can potentially enable contraction recovery and electromechanical coupling with host CMs. The functional outcomes of experimental MCS are reduction of ventricular wall stress and paracrine effects rather than contraction recovery. Several technical obstacles still hamper the clinical application of MCSs, with graft survival the most pivotal issue. Ischemia, apoptosis, inflammation, and immune response can all cause graft cell death, and a stable blood supply to the MCS is critical for successful engraftment. Ventricular tachycardia must also be considered in any myocardial cell therapy, and multiple layering of MCS (>3 layers) is necessary to reconstruct human myocardium. Innervation is also a potential issue. The future application of myocardial cell therapy with MCS for advanced HF depends on resolving these difficulties.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume303
Issue number10
DOIs
Publication statusPublished - 2012 Nov 15

Fingerprint

Cell- and Tissue-Based Therapy
Cardiac Myocytes
Heart Failure
Skeletal Myoblasts
Transplants
Induced Pluripotent Stem Cells
Pluripotent Stem Cells
Regenerative Medicine
Graft Survival
Ventricular Tachycardia
Embryonic Stem Cells
Developed Countries
Cause of Death
Myocardium
Cell Death
Stem Cells
Ischemia
Medicine
Apoptosis
Inflammation

Keywords

  • Cardiac function
  • Graft cell survival
  • Myocardial cell sheet
  • Pluripotent stem cells
  • Skeletal myoblasts

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Myocardial cell sheet therapy and cardiac function. / Fujita, Jun; Itabashi, Yuji; Seki, Tomohisa; Tohyama, Shugo; Tamura, Yuichi; Sano, Motoaki; Fukuda, Keiichi.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 303, No. 10, 15.11.2012.

Research output: Contribution to journalArticle

@article{8ea36eed2eb34fe0a0005ca179905519,
title = "Myocardial cell sheet therapy and cardiac function",
abstract = "Heart failure (HF) is the leading cause of death in developed countries. Regenerative medicine has the potential to drastically improve treatment for advanced HF. Stem cell-based medicine has received attention as a promising candidate therapy over the past decade; however, it has not yet realized this potential in terms of reliability. The cell sheet is an innovative technology for constructing aligned graft cells, and several cell sources have been investigated for making a feasible cell sheet. The most representative thus far is skeletal myoblast, although such cells raise the issue of arrhythmogenicity. Regenerative cardiomyocytes (CMs) derived from pluripotent stem cells (PSCs), such as embryonic stem cells or induced PSCs, are the most promising, because a myocardial cell sheet (MCS) constructed with regenerative CMs can potentially enable contraction recovery and electromechanical coupling with host CMs. The functional outcomes of experimental MCS are reduction of ventricular wall stress and paracrine effects rather than contraction recovery. Several technical obstacles still hamper the clinical application of MCSs, with graft survival the most pivotal issue. Ischemia, apoptosis, inflammation, and immune response can all cause graft cell death, and a stable blood supply to the MCS is critical for successful engraftment. Ventricular tachycardia must also be considered in any myocardial cell therapy, and multiple layering of MCS (>3 layers) is necessary to reconstruct human myocardium. Innervation is also a potential issue. The future application of myocardial cell therapy with MCS for advanced HF depends on resolving these difficulties.",
keywords = "Cardiac function, Graft cell survival, Myocardial cell sheet, Pluripotent stem cells, Skeletal myoblasts",
author = "Jun Fujita and Yuji Itabashi and Tomohisa Seki and Shugo Tohyama and Yuichi Tamura and Motoaki Sano and Keiichi Fukuda",
year = "2012",
month = "11",
day = "15",
doi = "10.1152/ajpheart.00376.2012",
language = "English",
volume = "303",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "10",

}

TY - JOUR

T1 - Myocardial cell sheet therapy and cardiac function

AU - Fujita, Jun

AU - Itabashi, Yuji

AU - Seki, Tomohisa

AU - Tohyama, Shugo

AU - Tamura, Yuichi

AU - Sano, Motoaki

AU - Fukuda, Keiichi

PY - 2012/11/15

Y1 - 2012/11/15

N2 - Heart failure (HF) is the leading cause of death in developed countries. Regenerative medicine has the potential to drastically improve treatment for advanced HF. Stem cell-based medicine has received attention as a promising candidate therapy over the past decade; however, it has not yet realized this potential in terms of reliability. The cell sheet is an innovative technology for constructing aligned graft cells, and several cell sources have been investigated for making a feasible cell sheet. The most representative thus far is skeletal myoblast, although such cells raise the issue of arrhythmogenicity. Regenerative cardiomyocytes (CMs) derived from pluripotent stem cells (PSCs), such as embryonic stem cells or induced PSCs, are the most promising, because a myocardial cell sheet (MCS) constructed with regenerative CMs can potentially enable contraction recovery and electromechanical coupling with host CMs. The functional outcomes of experimental MCS are reduction of ventricular wall stress and paracrine effects rather than contraction recovery. Several technical obstacles still hamper the clinical application of MCSs, with graft survival the most pivotal issue. Ischemia, apoptosis, inflammation, and immune response can all cause graft cell death, and a stable blood supply to the MCS is critical for successful engraftment. Ventricular tachycardia must also be considered in any myocardial cell therapy, and multiple layering of MCS (>3 layers) is necessary to reconstruct human myocardium. Innervation is also a potential issue. The future application of myocardial cell therapy with MCS for advanced HF depends on resolving these difficulties.

AB - Heart failure (HF) is the leading cause of death in developed countries. Regenerative medicine has the potential to drastically improve treatment for advanced HF. Stem cell-based medicine has received attention as a promising candidate therapy over the past decade; however, it has not yet realized this potential in terms of reliability. The cell sheet is an innovative technology for constructing aligned graft cells, and several cell sources have been investigated for making a feasible cell sheet. The most representative thus far is skeletal myoblast, although such cells raise the issue of arrhythmogenicity. Regenerative cardiomyocytes (CMs) derived from pluripotent stem cells (PSCs), such as embryonic stem cells or induced PSCs, are the most promising, because a myocardial cell sheet (MCS) constructed with regenerative CMs can potentially enable contraction recovery and electromechanical coupling with host CMs. The functional outcomes of experimental MCS are reduction of ventricular wall stress and paracrine effects rather than contraction recovery. Several technical obstacles still hamper the clinical application of MCSs, with graft survival the most pivotal issue. Ischemia, apoptosis, inflammation, and immune response can all cause graft cell death, and a stable blood supply to the MCS is critical for successful engraftment. Ventricular tachycardia must also be considered in any myocardial cell therapy, and multiple layering of MCS (>3 layers) is necessary to reconstruct human myocardium. Innervation is also a potential issue. The future application of myocardial cell therapy with MCS for advanced HF depends on resolving these difficulties.

KW - Cardiac function

KW - Graft cell survival

KW - Myocardial cell sheet

KW - Pluripotent stem cells

KW - Skeletal myoblasts

UR - http://www.scopus.com/inward/record.url?scp=84869179659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869179659&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00376.2012

DO - 10.1152/ajpheart.00376.2012

M3 - Article

C2 - 23001836

AN - SCOPUS:84869179659

VL - 303

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 10

ER -